Zycov D

Union Health Minister Mansukh Mandaviya on Thursday said the government does not want to make haste about administering COVID vaccines to children and any decision in this regard will be taken based on expert opinion.

ZyCov-D: Zydus Cadila's 3-dose needle-free COVID-19 vaccine to cost Rs 1,128

ZyCov-D will be administered using a needle-free applicator, called PharmaJet, instead of traditional syringes.

Zydus Cadila vaccine price finalised, rollout to begin soon: Mansukh Mandaviya

The price of Zydus Cadila vaccine is expected to be higher than Covishield and Covaxin

Zydus Cadila proposes Rs 1900 for three-dose COVID vaccine; Govt negotiating to bring it down

.

COVID-19 Vaccination | Children, adolescents with co-morbidities will be prioritised, says NTAGI chief

Dr NK Arora, the head of the technical advisory group on COVID-19 in India, clarified that children and adolescents with co-morbidities will be prioritised once the vaccination process for the age group begins and added that "some supply of Zycov-D will be prioritised for co-morbid adolescents".

ZyCoV-D, the needle-less DNA vaccine: how is it different from Covishield & Covaxin

India has approved the world’s first plasmid DNA vaccine, ZyCoV-D, for Emergency Use Authorization (EUA). Wondering how the vaccine works? Here's all you need to know.

Cadila: Vaccine opportunity unfolds

On conservative basis, for COVID vaccine opportunity, Cadila can at least add 16 per cent of FY21 sales revenue, on a full-year basis

Cadila: More a COVID hedge in the near term

Cadila's India presence -- at about 45 per cent of sales -- is similar in size as the US business and provides better cash-flow visibility

Zydus Cadila’s Sharvil Patel: We will manufacture one crore doses per month initially

Managing Director of Zydus Group Sharvil Patel says the company has invested Rs. 400-500 crore for the development of ZyCoV-D, the world’s first plasmid DNA vaccine for human use.

Needle-free, three doses—here’s all you need to know about Zydus Cadila’s COVID jab

Zydus Cadila conducted trials of ZyCoV-D at 50 sites spread across the country, making it the largest such trial in the country. It is also the first COVID vaccine in India to be tested among the 12-18 age group

Ideas For Profit | Cadila: COVID opportunity, complex pharma pipeline offer strong risk reward

Cadila’s stock was primed by a series of potential roll outs to meet the COVID-19 challenge. Beyond COVID, the company is steadily building up its injectable and biosimilars portfolio - the areas to look at for the longer term.

Zydus Cadila plans to test its COVID-19 vaccine on 30,000 volunteers in late stage trial

Cadila Healthcare said its vaccine was found to be well tolerated and immunogenic in the Phase I/II clinical trials.

COVID-19: Trial of COVAXIN and ZyCov-D marks 'beginning of the end', says scientist in article

The article has been published on the websites of the Press Information Bureau (PIB) and the Vigyan Prasar, which is a body under the ministry.